Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

Summary

This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients with RAS or RAF or NF-1 mutated advanced solid tumors as ABM-168 may have a significant effect in inhibiting cell growth.

Timeline

Start

2023-03-30

Primary completion

2024-06-30

Completion

2024-06-30

Outcome

Outcome not reported

Stopped (Business): “Due to development strategy change.”

Drugs

Indications